This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered In-Person & Digitally
March 28-30, 2022, Messe Basel, SwitzerlandApril 4–6, 2022, Digital

Francesco De Rubertis
Co-founder & Partner at Medicxi

Profile

Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Rivus Pharmaceuticals and is Chairman of Centessa Pharmaceuticals.

Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss:MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ:VSAR).

Francesco received a B.A. in Genetics and Microbiology from the University of Pavia (Italy) and a PhD in Molecular Biology from the University of Geneva (Switzerland) after which he became a postdoctoral scientist at the Whitehead Institute at M.I.T. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva (Switzerland).

In November 2017 Francesco was named in the first "Bloomberg 50” as one of the Top 50 entrepreneurs and innovators who helped to define Global Business in 2017.

For more info, you can follow Francesco on Twitter @fderubertis

Agenda Sessions

  • In the thick of it: Navigating beyond vaccine discovery

    17:00

Speakers at this event